135 related articles for article (PubMed ID: 11874430)
1. Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.
Abbink EJ; Pickkers P; Jansen van Rosendaal A; Lutterman JA; Tack CJ; Russel FG; Smits P
Diabet Med; 2002 Feb; 19(2):136-43. PubMed ID: 11874430
[TBL] [Abstract][Full Text] [Related]
2. Vascular K(ATP) channel blockade by glibenclamide, but not by acarbose, in patients with Type II diabetes.
Abbink EJ; Pickkers P; van Rosendaal AJ; Lutterman JA; Tack CJ; Russel FG; Smits P
Clin Sci (Lond); 2002 Mar; 102(3):307-14. PubMed ID: 11869171
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM.
Sundaresan P; Lykos D; Daher A; Diamond T; Morris R; Howes LG
Diabetes Care; 1997 May; 20(5):692-7. PubMed ID: 9135928
[TBL] [Abstract][Full Text] [Related]
4. Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.
Spallarossa P; Schiavo M; Rossettin P; Cordone S; Olivotti L; Cordera R; Brunelli C
Diabetes Care; 2001 Apr; 24(4):738-42. PubMed ID: 11315840
[TBL] [Abstract][Full Text] [Related]
5. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans.
Bijlstra PJ; Lutterman JA; Russel FG; Thien T; Smits P
Diabetologia; 1996 Sep; 39(9):1083-90. PubMed ID: 8877293
[TBL] [Abstract][Full Text] [Related]
6. Acute effects of oral glibenclamide on blood pressure and forearm vascular resistance in diabetics.
Sundaresan P; Lykos D; Daher A; Morris R; Diamond T; Howes LG
Clin Exp Pharmacol Physiol; 1997 May; 24(5):333-5. PubMed ID: 9143783
[TBL] [Abstract][Full Text] [Related]
7. Acute effects of oral glibenclamide on blood pressure and forearm vascular resistance in diabetics.
Sundaresan P; Lykos D; Daher A; Morris R; Diamond T; Howes LG
Clin Exp Pharmacol Physiol; 1998 Feb; 25(2):170-4. PubMed ID: 9493510
[TBL] [Abstract][Full Text] [Related]
8. Effects of glibenclamide on blood pressure and cardiovascular responsiveness in non-insulin dependent diabetes mellitus.
Williams S; Abbott D; Morfis L; Manwaring P; Diamond T; Howes LG
J Hypertens; 1998 May; 16(5):705-11. PubMed ID: 9797183
[TBL] [Abstract][Full Text] [Related]
9. Effects of tolbutamide on vascular ATP-sensitive potassium channels in humans. Comparison with literature data on glibenclamide and glimepiride.
Bijlstra PJ; Russel FG; Thien T; Lutterman JA; Smits P
Horm Metab Res; 1996 Sep; 28(9):512-6. PubMed ID: 8911989
[TBL] [Abstract][Full Text] [Related]
10. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study.
Dhindsa P; Davis KR; Donnelly R
Br J Clin Pharmacol; 2003 Jun; 55(6):616-9. PubMed ID: 12814458
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
[TBL] [Abstract][Full Text] [Related]
13. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
Massi-Benedetti M; Herz M; Pfeiffer C
Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
[TBL] [Abstract][Full Text] [Related]
14. Glyburide inhibits dipyridamole-induced forearm vasodilation but not adenosine-induced forearm vasodilation.
Bijlstra P; van Ginneken EE; Huls M; van Dijk R; Smits P; Rongen GA
Clin Pharmacol Ther; 2004 Mar; 75(3):147-56. PubMed ID: 15001965
[TBL] [Abstract][Full Text] [Related]
15. KATP channel activation induces ischemic preconditioning of the endothelium in humans in vivo.
Broadhead MW; Kharbanda RK; Peters MJ; MacAllister RJ
Circulation; 2004 Oct; 110(15):2077-82. PubMed ID: 15466634
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide.
Draeger KE; Wernicke-Panten K; Lomp HJ; Schüler E; Rosskamp R
Horm Metab Res; 1996 Sep; 28(9):419-25. PubMed ID: 8911976
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy].
González-Ortiz M; Martínez-Abundis E;
Rev Invest Clin; 2004; 56(3):327-33. PubMed ID: 15612515
[TBL] [Abstract][Full Text] [Related]
18. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide.
Klepzig H; Kober G; Matter C; Luus H; Schneider H; Boedeker KH; Kiowski W; Amann FW; Gruber D; Harris S; Burger W
Eur Heart J; 1999 Mar; 20(6):439-46. PubMed ID: 10213347
[TBL] [Abstract][Full Text] [Related]
19. Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients.
Wascher TC; Boes U
Clin Physiol Funct Imaging; 2005 Jan; 25(1):40-6. PubMed ID: 15659079
[TBL] [Abstract][Full Text] [Related]
20. Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients.
Nagayama D; Saiki A; Endo K; Yamaguchi T; Ban N; Kawana H; Ohira M; Oyama T; Miyashita Y; Shirai K
Int J Clin Pract; 2010 Dec; 64(13):1796-801. PubMed ID: 20946343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
